Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04051619 · ClinicalTrials.gov registry record · Phase 1
Oxytocin, Stress, Craving, Opioid Use Disorder
A Phase 1 study, sponsored by Brown University.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT04051619 is a Phase 1 study that has completed, run by Brown University. The registered enrollment target is 20 participants.
The verdict
NCT04051619, a Phase 1 study, has completed, sponsored by Brown University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
Although stress has long been linked to substance use, craving and relapse, there are no available medications that target stress-induced substance use disorder (SUD). In particular, with the rise in opioid use, there is still a crucial need for developing effective pharmacological treatments that target and integrate the complexity of this disease. The long term goal of this project is to identify the key neuroendocrine pathways that are responsible for stress-induced craving in individuals with opioid use disorder (OUD) in order to better understand how they can be effectively treated.
Interventions
- DRUG intranasal oxytocin, 40 IU, twice a day for 7 days
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2020-01-06 |
| Est. Completion | 2023-12-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04051619
The ClinicalTrials.gov registry entry for NCT04051619 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brown University, which has 231 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which intranasal oxytocin, 40 IU, twice a day for 7 days is the first listed.
NCT04051619 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04051619 about?
NCT04051619 is a clinical study titled "Oxytocin, Stress, Craving, Opioid Use Disorder". Although stress has long been linked to substance use, craving and relapse, there are no available medications that target stress-induced substance use disorder (SUD). In particular, with the rise in opioid use, there is still a crucial need for developing effective pharmacological treatments that t...
What is the current status of trial NCT04051619?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2020-01-06. Estimated completion is 2023-12-23.
What interventions are being tested in trial NCT04051619?
The interventions under investigation include: intranasal oxytocin, 40 IU, twice a day for 7 days (DRUG).
Who is sponsoring clinical trial NCT04051619?
This trial is sponsored by Brown University, which has 231 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.